The Pharmaceutical Task Group (PTG), has urged the Health Department to immediately reconsider the newly gazetted increase of only 1.47%, in the maximum Single Exit Price (SEP) for medicines in 2026. – Business Day (8 Dec 2025)
The PTG, which represents 90% of the industry, was expecting a maximum SEP increase of 3.2%, mirroring the current inflation rate. This figure, they argue, was both fair and reasonable for maintaining the sector's operational viability. Stavros Nicolaou, chair of the PTG, stressed the fundamental need for consistency in applying the SEP pricing methodology. He said any investor, or any supplier of goods and services as critical as medicines, requires that element of consistency.
The industry is not only seeking a financial adjustment but also asking for clarification on how the pricing committee arrived at its decision.